ScinoPharm Taiwan, Ltd. (1789.TW)
TWD 21.85
(-1.35%)
TWD 21.85
(-1.35%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.21 Billion TWD | -2.78% |
| 2022 | 1.25 Billion TWD | -2.32% |
| 2021 | 1.28 Billion TWD | -2.81% |
| 2020 | 1.31 Billion TWD | 11.99% |
| 2019 | 1.17 Billion TWD | -23.73% |
| 2018 | 1.54 Billion TWD | -0.49% |
| 2017 | 1.55 Billion TWD | -14.16% |
| 2016 | 1.8 Billion TWD | 7.71% |
| 2015 | 1.67 Billion TWD | 4.75% |
| 2014 | 1.6 Billion TWD | -37.05% |
| 2013 | 2.54 Billion TWD | 9.9% |
| 2012 | 2.31 Billion TWD | 16.58% |
| 2011 | 1.98 Billion TWD | -2.44% |
| 2010 | 2.03 Billion TWD | 7.08% |
| 2009 | 1.89 Billion TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 353.31 Million TWD | -22.8% |
| 2024 Q2 | 268.05 Million TWD | -24.13% |
| 2024 Q3 | 278.98 Million TWD | 4.08% |
| 2023 Q2 | 282.94 Million TWD | 16.01% |
| 2023 Q4 | 457.67 Million TWD | 97.72% |
| 2023 Q3 | 231.47 Million TWD | -18.19% |
| 2023 Q1 | 243.89 Million TWD | -33.53% |
| 2023 FY | 1.21 Billion TWD | -2.78% |
| 2022 Q3 | 240.44 Million TWD | -30.48% |
| 2022 FY | 1.25 Billion TWD | -2.32% |
| 2022 Q2 | 345.87 Million TWD | 16.24% |
| 2022 Q1 | 297.54 Million TWD | -11.33% |
| 2022 Q4 | 366.91 Million TWD | 52.6% |
| 2021 Q3 | 243.03 Million TWD | -27.91% |
| 2021 FY | 1.28 Billion TWD | -2.81% |
| 2021 Q1 | 364.76 Million TWD | 40.36% |
| 2021 Q2 | 337.11 Million TWD | -7.58% |
| 2021 Q4 | 335.56 Million TWD | 38.07% |
| 2020 Q2 | 438.14 Million TWD | 79.31% |
| 2020 Q4 | 259.87 Million TWD | -30.72% |
| 2020 FY | 1.31 Billion TWD | 11.99% |
| 2020 Q3 | 375.08 Million TWD | -14.39% |
| 2020 Q1 | 244.35 Million TWD | -12.83% |
| 2019 Q2 | 273.98 Million TWD | -16.91% |
| 2019 Q4 | 280.31 Million TWD | -4.12% |
| 2019 FY | 1.17 Billion TWD | -23.73% |
| 2019 Q3 | 292.35 Million TWD | 6.71% |
| 2019 Q1 | 329.75 Million TWD | -25.98% |
| 2018 FY | 1.54 Billion TWD | -0.49% |
| 2018 Q4 | 445.48 Million TWD | 30.4% |
| 2018 Q3 | 341.64 Million TWD | -18.82% |
| 2018 Q2 | 420.84 Million TWD | 25.8% |
| 2018 Q1 | 334.54 Million TWD | -3.49% |
| 2017 Q3 | 407.44 Million TWD | 25.1% |
| 2017 FY | 1.55 Billion TWD | -14.16% |
| 2017 Q2 | 325.7 Million TWD | -30.76% |
| 2017 Q1 | 470.39 Million TWD | 6.0% |
| 2017 Q4 | 346.62 Million TWD | -14.93% |
| 2016 Q1 | 431.26 Million TWD | -16.13% |
| 2016 FY | 1.8 Billion TWD | 7.71% |
| 2016 Q4 | 443.74 Million TWD | -4.82% |
| 2016 Q3 | 466.21 Million TWD | 0.32% |
| 2016 Q2 | 464.74 Million TWD | 7.76% |
| 2015 Q2 | 364.82 Million TWD | 5.94% |
| 2015 FY | 1.67 Billion TWD | 4.75% |
| 2015 Q1 | 344.37 Million TWD | 17.0% |
| 2015 Q4 | 514.22 Million TWD | 13.46% |
| 2015 Q3 | 453.24 Million TWD | 24.24% |
| 2014 Q4 | 294.33 Million TWD | -21.13% |
| 2014 Q3 | 373.21 Million TWD | -25.35% |
| 2014 Q2 | 499.95 Million TWD | 15.45% |
| 2014 FY | 1.6 Billion TWD | -37.05% |
| 2014 Q1 | 433.05 Million TWD | -31.63% |
| 2013 Q4 | 633.43 Million TWD | 19.52% |
| 2013 FY | 2.54 Billion TWD | 9.9% |
| 2013 Q1 | 654.81 Million TWD | -8.12% |
| 2013 Q2 | 724.28 Million TWD | 10.61% |
| 2013 Q3 | 529.99 Million TWD | -26.83% |
| 2012 Q2 | 437.45 Million TWD | -16.37% |
| 2012 Q1 | 523.07 Million TWD | -12.42% |
| 2012 Q4 | 712.7 Million TWD | 11.33% |
| 2012 Q3 | 640.19 Million TWD | 46.34% |
| 2012 FY | 2.31 Billion TWD | 16.58% |
| 2011 Q4 | 597.23 Million TWD | 18.47% |
| 2011 FY | 1.98 Billion TWD | -2.44% |
| 2011 Q1 | 370.55 Million TWD | -31.01% |
| 2011 Q2 | 512.49 Million TWD | 38.3% |
| 2011 Q3 | 504.13 Million TWD | -1.63% |
| 2010 Q3 | 593.93 Million TWD | 0.0% |
| 2010 FY | 2.03 Billion TWD | 7.08% |
| 2010 Q4 | 537.08 Million TWD | -9.57% |
| 2009 FY | 1.89 Billion TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Grape King Bio Ltd | 8.53 Billion TWD | 85.75% |
| Standard Chem & Pharm CO., LTD. | 2.72 Billion TWD | 55.383% |
| Maywufa Company Ltd. | 854.37 Million TWD | -42.325% |
| Lotus Pharmaceutical Co., Ltd. | 8.33 Billion TWD | 85.418% |
| LIWANLI Innovation Co., Ltd. | 15.08 Million TWD | -7961.984% |
| YungShin Global Holding Corporation | 2.91 Billion TWD | 58.229% |
| PhytoHealth Corporation | 67.64 Million TWD | -1697.657% |
| SCI Pharmtech, Inc. | 350.32 Million TWD | -247.105% |
| Formosa Laboratories, Inc. | 1.9 Billion TWD | 36.111% |
| PharmaEssentia Corporation | 4.49 Billion TWD | 72.948% |
| Bora Pharmaceuticals Co., LTD. | 6.99 Billion TWD | 82.607% |